Schering Corporation

Elliot I Stupak

Imtiaz A Chaudry

Winston A Vadino

Stephen M Liebowitz

Frank E Bowen

Joel A Sequeira

Farah J Munayyer

Frank Guazzo

Varda E Sandweiss

Bernard E Rosenkrantz

Paul H Shapiro

Eric M Bonnem

W Philip Cho

An antihistaminic syrup is stabilized against degradation of the active ingredient, by the addition of and about 0.05 to about 5 mg/mL of an aminopolycarboxylic acid such as a salt of ethylenediaminetetraacetic acid.

Stabilized antihistamine syrup

An orally administrable solid dosage form containing a compacted ribavirin composition having an advantageously high tap density of at least 0.6 g/mL as well as surprisingly rapid disintegration and dissolution rates and wherein the ribavirin is substantially free of polymorphic forms of ribavirin and a process for making such solid dosage forms are disclosed.

Orally administrable solid ribavirin dosage forms and process for making them

An orally administrable solid dosage form containing a compacted ribavirin composition having an advantageously high tap density of at least 0.6 g/mL as well as surprisingly rapid disintegration and dissolution rates and wherein the ribavirin is substantially free of polymorphic forms of ribavirin is disclosed.

Orally administrable solid dosage form

An orally administrable solid dosage form containing a compacted ribavirin composition having an advantageously high tap density of at least 0.6 g/mL as well as surprisingly rapid disintegration and dissolution rates and wherein the ribavirin is subsantially free of polymorphic forms of ribavirin is disclosed.

A process of making an orally administrable solid dosage form containing a compacted ribavirin composition having an advantageously high tap density of at least 0.6 g/mL as well as surprisingly rapid disintegration and dissolution rates and wherein the ribavirin is substantially free of polymorphic forms of ribavirin as determined is disclosed.

Process of making solid ribavirin dosage forms

Use of GM-CSF as a vaccine adjuvant

A controlled release solid dosage tablet of flutamide is disclosed that is designed to provide an immediate release dose and a second delayed dose in pulsatile manner in the gastrointestinal tract for twice a day use.

Controlled release flutamide composition

Disclosed is an elegant formulation of betamethasone dipropionate useful as a topical anti-inflammatory product.

Betamethasone dipropionate cream

Disclosed is an elegant cream-like formulation of betamethasone dipropionate useful as a topical antiinflammatory product.

A highly pH- and color-stabilized parenteral formulation is provided comprising an aqueous solution of a salt of an aminoglycoside containing an allylic amine and having a pH between 5.0-7.0.

Growing community of inventors

West Caldwell, NJ, United States of America

Elliot I Stupak